重型再生障碍性贫血与低危低增生性骨髓增生异常肿瘤的比较:巨核细胞计数在区分再生障碍性贫血与骨髓增生异常肿瘤中的关键作用
本研究比较了经严格标准(结合骨髓细胞量和巨核细胞计数,巨核细胞减少方可确诊再生障碍性贫血)判定的39例重型再生障碍性贫血(SAA)与41例低危低增生性骨髓增生异常肿瘤(LR-hMDS)患者的预后。两组总生存率和无白血病生存率差异显著(p < 0.0001)。即使在接受免疫抑制治疗的患者中,5年后预后差异明显,但治疗反应无显著差异。巨核细胞计数对鉴别MDS与AA至关重要。
要点
- 严格标准下巨核细胞减少是确诊再生障碍性贫血的关键条件。
- SAA与LR-hMDS两组总生存率和无白血病生存率差异显著(p < 0.0001)。
- 免疫抑制治疗患者5年后预后差异明显,但治疗反应无显著差异。
核心结论
- 巨核细胞计数对区分骨髓增生异常肿瘤与再生障碍性贫血至关重要。
研究设计与样本
- 研究比较了39例重型再生障碍性贫血患者(从既往报告的100例AA队列中提取)与41例低危低增生性骨髓增生异常肿瘤患者的预后,所有患者同期入组。
- 采用严格标准排除MDS,综合考虑骨髓细胞量和巨核细胞计数,仅在巨核细胞计数减少后方确诊AA。
主要发现
- 两组总生存率和无白血病生存率差异显著(p < 0.0001)。
- 即使在接受免疫抑制治疗的患者中,5年后预后差异明显,但治疗反应无显著差异。
关键数值与推荐
- 确诊AA需在严格标准下确认巨核细胞计数减少。
- 两组总生存率和无白血病生存率差异的p值均< 0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although genetic abnormalities are increasingly crucial for diagnosing and classifying haematopoietic diseases, dysplasia remains crucial for distinguishing myelodysplastic neoplasms (MDS) from aplastic anaemia (AA). Erythroid dysplasia may be observed in AA, complicating the differentiation between these conditions. In a previous study using the data from the Japan Idiopathic Myelodysplastic Syndrome Study Group's registry, we found that erythroid dysplasia does not affect the prognosis of AA. This current study was designed to compare the prognosis of patients with lower risk hypoplastic MDS (LR-hMDS), as determined by our review, and patients with severe AA (SAA), all enrolled concurrently, to validate our diagnostic approach. Stringent criteria were used to rule out MDS, considering bone marrow cellularity and megakaryocyte counts, with a confirmed AA diagnosis only following a reduced megakaryocyte count. The study comprised 39 severe cases extracted from a cohort of 100 AA patients previously reported and 41 patients with LR-hMDS. Significant differences in overall and leukaemia-free survival were observed between the two groups (p < 0.0001). Even among patients undergoing immunosuppressive therapy, a marked prognostic distinction became evident after 5 years, although their response to the therapy did not differ significantly. Therefore, the megakaryocyte count is pivotal in differentiating MDS from AA.
引用
- Maeda T, Matsuda A, Kanda J, et al. Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms. Br J Haematol. 2025. PMID: 40259860. doi:10.1111/bjh.20097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。